Magenta Therapeutics Inc (OQ:MGTA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 100 Technology Sq Fl 5
CAMBRIDGE MA 02139-3585
Tel: N/A
IR: See website
Key People
Michael W. Bonney
Independent Chairman of the Board
Jason Gardner
President, Chief Executive Officer, Co-Founder, Director
Jason Michael Ryan
Chief Financial Officer, Chief Operating Officer
Jan Pinkas
Chief Scientific Officer
John C. Davis
Chief Medical Officer
Christina K. Isacson
Chief Business Officer
Zoran Zdraveski
Secretary and Chief Legal Officer
Business Overview
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company's products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company's C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
Financial Overview
For the nine months ended 30 September 2019, Magenta Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 31% to $53.5M. Higher net loss reflects Research and development - Balancin increase of 51% to $36.7M (expense), General and increase of 44% to $13.7M (expense), Stock-based Compensation in SGA increase of 16% to $4.1M (expense).
Employees: 72 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $389.96M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$74.55M as of Sep 30, 2019
Net annual income (TTM): -$70.21M as of Sep 30, 2019
Free cash flow (TTM): -$61.36M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 38,942,719 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization